TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03483623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NATO WELP combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NATO FIS combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAVEN WELP combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
Study: NCT02412696

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure
Description: Auto-titrating PAP + nasal dilator strips during sleep

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Dilator Strips
Description: Nasal dilator strips

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Dilator Strips
Description: Nasal dilator strips
Study: NCT02965573

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARGX-113

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01582828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epicardial (surgical) ablation
Description: * Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid
Description: Epicardial (surgical) ablation~* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation
Study: NCT04272255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: scopolamine HBr
Description: Nasal Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: scopolamine HBr
Description: Nasal Gel
Study: NCT03104192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Develop & Refine MOWI w/o Amulet
Description: The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
Study: NCT04272255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Scopolamine
Description: Patch
Study: NCT04183218

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection

Intervention type: DEVICE
Intervention: Cardiac Event Monitor
Description: Receive cardiac monitor
Study: NCT03483623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAVEN FIS combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
Study: NCT02440152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suzhou Sceneray® DBS System
Description: We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
Study: NCT04598152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS - transcranial direct current stimulation
Description: TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
Study: NCT03891524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 25 mg
Description: Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 25 mg
Description: Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 50 mg
Description: Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 50 mg
Description: Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 100 mg
Description: Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 200 mg
Description: Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 200 mg
Description: Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-70033093, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-70033093, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-70033093, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-70033093, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-70033093, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg
Description: Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
Study: NCT04183218

Intervention type: OTHER
Intervention: Chemoradiotherapy
Description: Undergo CRT

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT03649607

Intervention type: OTHER
Group type: OTHER
Intervention: Accelerated Resolution Therapy
Description: ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
Study: NCT02802007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elipse Intragastric Balloon
Study: NCT03104192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOWI Weight Loss Maintenance
Description: Participants who successfully completed the initial MOWI program will be offered the opportunity to participate in a 6-month weight management program. This program will consist of 8 group-based skills workshop sessions occurring approximately once monthly (every 3 weeks), which will be 90-120 minutes in length. The overall structure of the program will emphasize the following evidence-based weight management components: Goal setting/action planning, self-monitoring, receiving feedback regarding performance, reviewing relevant goals in the light of feedback, and e. psychological skills for increasing behavioral commitment (acceptance, willingness, thought monitoring, mindful decision making, and values clarification).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Develop & Refine MOWI w Fitbit
Description: The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance.
Study: NCT03600285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TB1-K
Description: Use of TB1-K for preservation and transport of donated kidneys
Study: NCT00932893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066, 250 mg BID will be administered orally on a continuous schedule
Study: NCT03102788

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rheumatologist-led care.
Description: Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapist-led care.
Description: Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
Study: NCT03104192

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Develop & Refine MOWI w Fitbit/Protein
Description: The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance. We will provide whey protein 3x/week after exercise sessions.
Study: NCT03973086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus flavonone-O-glycosides- LD
Description: Low Dose of 200 mg
Study: NCT01294241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Description: 1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex® soft silicone faced polyurethane foam dressing
Description: Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® soft silicone faced polyurethane foam dressing
Description: Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
Study: NCT01109693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline 50 mg/d or 100 mg/d for 6 more weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline 50 mg/d or 100 mg/d for 6 more weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Augment with or switch to mirtazapine 15-45 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Augment with or switch to mirtazapine 15-45 mg/d
Study: NCT00648791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride Tablets 5 mg
Description: 5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proscar Tablets 5 mg
Description: 5mg, single dose fasting
Study: NCT02253511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidan capsule
Study: NCT03973086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus flavonone-O-glycosides- HD
Description: High Dose of 400 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Microcrystalline Cellulose) of 400 mg
Study: NCT00696631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone (SR33589)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT01770197

Intervention type: DRUG
Intervention: IV rt-PA
Description: IV rt-PA treatment

Intervention type: DRUG
Intervention: IV rt-PA
Description: IV rt-PA treatment
Study: NCT01935882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
Study: NCT04215107

Intervention type: OTHER
Group type: OTHER
Intervention: Standard breakfast meal
Description: The first ultrasound will be preformed during fasting. IUGR group will be served a standard breakfast meal, and perform the second ultrasound after 2 hours from the meal.~The control group will be crossover randomized to meal or prolonged fasting. It will be performed 4 ultrasounds: during fasting and 2 hours after standard breakfast meal. During fasting and during prolonged fasting.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard breakfast meal
Description: The first ultrasound will be preformed during fasting. IUGR group will be served a standard breakfast meal, and perform the second ultrasound after 2 hours from the meal.~The control group will be crossover randomized to meal or prolonged fasting. It will be performed 4 ultrasounds: during fasting and 2 hours after standard breakfast meal. During fasting and during prolonged fasting.
Study: NCT01933932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Description: All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Description: All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
Study: NCT04114578

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
Study: NCT03938883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Bandage Gel (OBG)
Description: A modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bandage Contact Lens (BCL)
Description: A bandage contact lens protects an injured or diseased cornea from the mechanical rubbing of the blinking eyelids, therefore allowing it to heal. It is a normal (usually soft, but not always) contact lens has no power. It is not intended to improve your vision.
Study: NCT04114578

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
Study: NCT04318041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artrodar
Description: Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal
Study: NCT00932893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
Study: NCT03283670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide 25%
Description: Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.